Home > Escp Profiles > MAGIA

Medtech Alliance for Global InternationAlisation
ESCP-4i Status: 
Preparation Phase - Strand1
Start of Partnership: 
Previous initiatives: 
European Cluster Consortia 2012: 
ESCP Pilots 2013: 
ESCP-4i Charter: 
Partnership duration
24 months
Number of partners
Number of SMEs involved

The global medical technologies sector (i.e. medical devices, In Vitro Diagnostics and medical imaging equipment) can be a tough environment for Small and Medium-sized Enterprises and start-ups. In Europe the industry – considered to be one of the Top10 emerging ones - is mainly composed of SMEs, which face several obstacles: strong and fast international competition, strict and multi-faceted regulatory environment, the need of integrating diverse technologies, as well as their traditional difficulties: lack of time, money and specialized human resources being the most relevant ones. The role of clusters is thus crucial in supporting companies with their internationalization effort and in providing them with the proper tools. MAGIA (from the Italian magìa = “magic”) – Medtech Alliance for Global InternationAlisation - brings together 4 European leading medtech and health clusters with the objective of fostering internationalization of their SMEs through a strong alliance of European value. The overall goal of the project is to strengthen, through cooperation and resource-sharing, the competitiveness on 2 target global markets (China and USA) of clusters’ SMEs operating in the field and to make the innovative European medtech industry more visible. Participating clusters mutualise their knowledge, skills, best practices and their dynamic medtech companies to achieve the necessary critical mass to foster internationalization, achieving a proper positioning on the global scale and provide a coordinated, joint and stronger strategic support to companies. The consortium also intends to create and represent a single European entry point for global players in the medtech sector. Long experience and solid cluster management, mutual knowledge of strengths and assets, a clear focus on two target countries, in depth market studies and a sound and scalable Joint Internationalisation Strategy are the key components of our proposal.

Sectoral Industries: 
Information Technology and Analytical Instruments
Technology Fields: 
BIOLOGICAL SCIENCESMedicine, Human HealthMedical Technology / Biomedical Engineering
S3 EU priority areas: 
Human health & social work activities:Human health activities (medical services)
Emerging industries: 
Medical Devices
Partnership planned events: 
Target GroupTypeEstimated DateCountryCity
Cluster Organisations
Study Visits
February 2018
Cluster Organisations
Study Visits
April 2018
Cluster Organisations
Study Visits
September 2018
Cluster Organisations
Study Visits
June 2018
Colleretto Giacosa
Cluster Organisations
Study Visits
April 2019
United States
Cluster Organisations
Study Visits
May 2019
Beijing - Shanghai
Partnership other activities: 

The partners will develop the project through 5 work packages.

WP1 is dedicated to partnership building and identification of common opportunities through the identification of common needs as the starting point of the project. All the four partners have a long operating history and possess an internationalization strategy; however, they have identified the necessity to join forces and work together, in order to reach an important critical mass. Mutual study visits as well as a detailed assessment of internationalization needs of the clusters’ SMEs and the selection of two target countries are envisaged.

WP2: following the outcomes of WP1 the cluster consortium will have the necessary information to perform a targeted series of intelligence and training actions to prepare the clusters and the SMEs towards market needs. Two market studies will be commissioned and a series of dedicated training actions will be arranged, including two fact-finding/networking missions abroad.

In WP3 the partners will capitalize the results of WP1 and WP2 and define a Joint Internationalization Strategy with a long-term perspective and a sustainability approach, as well as a cooperation agenda and a proper set of KPIs. We aim for a scalable and transferable model, so others can benefit from the results of our shared experience.  

WP 4 is dedicated to the definition of the communication activities and marketing approach and plays a major role in the construction of the strategic partnership. A common identity and key messages will be developed and transferred into dedicated marketing tools, together with a sound dissemination plan.

WP5, dedicated to project management, will ensure control and consistency between planned activities and achievements as well as proper reporting and financial control.

Specific project objectives By sharing their respective knowledge and experiences, such as the approach developed through the bioXclusters Alliance, the consortium will deploy activities with the objectives of forming a European Strategic Cluster Partnership on Medtech based on a common vision for a long term relation. Their main objectives will be:

  • Set up the basis of the Strategic partnership by analysing in depth each partner organisation; identifying opportunities through the identification and sharing of cluster’s skills and competences, as well as strengths and needs (in particular regarding internationalisation) from respective ecosystem in medtech; from these needs the partners will identify precisely the markets to target from a shortlist of countries that the consortium has already identified as relevant for the medtech sector (USA, Canada, China, Japan, Brazil, Middle East countries).
  • Generate opportunities for the cluster partners and their SMEs to gain knowledge about the target markets, thanks to dedicated training sessions, the presence of experts and fact-finding missions focused on medtech company international development.
  • Developing a common marketing and branding approach, in order to build up the visual and marketing identity of the ESCP as metacluster that could represent the strategic “core” of future pan-European initiatives.
  • Defining a joint internationalisation strategy for the ESCP including the Partnership Agreement (PA), expressing the willingness of the partners to engage in a long-term cooperation effort and the ESCP’s strategy implementation roadmap.
Other key partners or networks your partnership is linked with in Europe and in third countries: 

Partnership composition

Name Sector/Technology fields Country Regions Total no. of members Total no. of SME
Life Science Nord Biopharmaceuticals, Business Services

Diagnostics, Diagnosis, Medical Technology / Biomedical Engineering

Digital Agendae-Health (e.g. healthy ageing), Human health & social work activities:Human health activities (medical services)

Biopharmaceuticals, Medical Devices
Germany Hamburg 270 174
BioWin Biopharmaceuticals

Medical Technology / Biomedical Engineering, Pharmaceutical Products / Drugs

Digital Agendae-Health (e.g. healthy ageing), KETSAdvanced manufacturing systems

Biopharmaceuticals, Digital Industries
Belgium Prov. Hainaut 234 187
bioPmed / Bioindustry Park Biopharmaceuticals, Business Services

Diagnostics, Diagnosis, Medical Technology / Biomedical Engineering

Public health and securityAgeing societies, Public health and securityPublic health and well-being

Biopharmaceuticals, Medical Devices
Italy Piemonte 100 89
LYONBIOPOLE Biopharmaceuticals

Cellular and Molecular Biology, Health information management

Digital Agendae-Health (e.g. healthy ageing), Human health & social work activities:Human health activities (medical services)

Biopharmaceuticals, Digital Industries
France Rhône-Alpes 245 220